Comparing to HD, treated CML patients exhibited an increase of NKT-like cells expressing NKp30 (Percentage: 0.2 ± 0.1 vs. 0.9 ± 1.2; p < 0.0001), NKp44 (Percentage: 0.1 ± 0.1 vs. 0.4 ± 0.6; p = 0.007), and NKp46 (Percentage: 0.2 ± 0.2 vs. 0.9 ± 1.2; p = 0.002) receptors (Figure 5C). This evidence concerns the gene NCR2 and chronic myelogenous leukemia, BCR-ABL1 positive.